The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Using Direct Reprogramming To Generate And Rejuvenate Haematopoietic Stem Cells
Funder
National Health and Medical Research Council
Funding Amount
$1,026,313.00
Summary
One of the greatest promises of regenerative medicine lies in our ability to reprogram any cell type of the body into any other cell type. Transdifferentiation is the conversion of one adult cell type to another and it is believed to be the next frontier in regenerative medicine therapies since it can be used in vivo for the direct conversion of one cell type into another. The outcomes of this grant will push the limits of these technologies to generate new regenerative medicine strategies.
Haematopoietic Stem Cell Glycome Regulates Outcome Of Niche Interactions
Funder
National Health and Medical Research Council
Funding Amount
$913,729.00
Summary
Hematopoietic stem cells (HSC) reside in the bone marrow (BM) and make all the cells of the blood system. We have found a factor in the BM which when blocked, puts normal HSC to sleep helping them survive chemotherapy. This means cancer patients should suffer less side-effects from their therapy. This factor also helps leukaemia stem cells (LSC) resist chemotherapy. Inhibitors may a) reduce patient mortality caused by chemotherapy and b) sensitise LSC to chemotherapy enabling long-term cure.
(Re)wiring A Stem Cell: Deciphering The Molecular Mechanism Underpinning Lineage Propensity
Funder
National Health and Medical Research Council
Funding Amount
$855,780.00
Summary
This project explores the response of the stem cells to cues that direct how they turn into specific type of cells that is suitable for clinical use. Specifically, a set of driver genes whose activity can foretell the outcome of cell differentiation will be identified. By modulating the maintenance conditions, iPSCs lines may be tailored for specific applications in stem cell therapy and disease modelling for the assessment of treatment efficacy.
Osteochondroreticular Stem Cell Therapy For Osteoarthritis: The Right Cells For The Job.
Funder
National Health and Medical Research Council
Funding Amount
$561,956.00
Summary
"Wear and tear" arthritis of the knee, hip and back joints is known as osteoarthritis. This causes significant health burden and costs in our community, particularly in older Australians. Osteoarthritis begins with the loss of joint cartilage. We believe that a new type of stem cells (OCR stem cells) offer the greatest promise to generate and thus therapeutically replace joint cartilage. Our studies test this hypothesis and develop preclinical translation of our discoveries in mice into humans.
Reprogramming is the conversion of any cell into induced pluripotent stem cells (iPSC). iPSC carry immense clinical potential as they are pluripotent and can hence form any cell of the human body, however, they can also form tumours. We have identified a cell type during reprogramming which is pluripotent but cannot form tumours. It is the aim of this project to characterize these cells as well as to confirm their existence during human reprogramming.
Tapping The Power Of Pluripotency: The Role Of HMGA1 In Stem Cell Self-renewal And Cell Fate Transitions
Funder
National Health and Medical Research Council
Funding Amount
$520,314.00
Summary
Stem-cell-based therapies have great potential as new treatments for degenerative and genetic diseases. However, to ensure we move in the right direction, we need a detailed understanding of stem cell properties. We have recently identified a novel mechanism for controlling stem-cell-like properties in both normal and cancer stem cells. In this project, we will further investigate this new means of controlling stem cells, which could revolutionise future therapeutic strategies for many diseases.
The Characterisation Of An Essential Regulator Of Pre-mRNA Splicing Required For Germ Cell Function And Male Fertility
Funder
National Health and Medical Research Council
Funding Amount
$1,116,739.00
Summary
The male germ line is a fantastic system within which to define processes of fundamental importance to cell biology and health broadly. Within this grant we will define the role of a poorly described RNA splicing factor in all of stem cell function (spermatogonia), meiosis (spermatocytes) and in the remarkable metamorphosis underlying spermatid maturation. This will be done using a range of phenotypic characterizations, CHIP and RNA Seq technologies and gene sequencing.
Twist-1 Inhibits MSC Osteoblast Differentiation During Osteoporosis Via Direct Regulation Of The Wnt Signalling Pathway
Funder
National Health and Medical Research Council
Funding Amount
$482,704.00
Summary
There is a predicted dramatic increase in the number of orthopaedic related problems that require surgical intervention and rehabilitation therapy in the coming decade associated with higher incidences of bone diseases as a consequence of an aging population. This proposal seeks to determine whether the transcription factor, Twist-1 plays a central role in regulating the growth and differentiation of skeletal progenitors during bone loss following the onset of osteoporosis.
Targeting Disease-initiating Cells In Myeloproliferative Neoplasms
Funder
National Health and Medical Research Council
Funding Amount
$477,170.00
Summary
The myeloproliferative neoplasms (MPN) are a related group of blood disorders. Despite the advent of targeted therapies, patients have significant ongoing morbidity, mortality and financial cost. A key reason underlying the persistence of disease is the presence of a stem cell pool that is resistant to targeted therapy. Clinical data has suggested that interferon may target these disease stem cells. We propose to use in vivo, validated disease models to investigate the role of interferon in MPN.
Mechanisms By Which Endothelial Selectins Regulate Normal And Malignant Stem Cell Fate
Funder
National Health and Medical Research Council
Funding Amount
$708,742.00
Summary
Hematopoietic stem and progenitor cells (HSPC) reside in the bone marrow (BM) and make all the cells of the blood system. We have found a molecule in the BM which when increased during inflammation, awakens normal HSPC. We previously showed this molecule also helps leukaemia and other cancer stem cells resist chemotherapy. We have now identified the mechanism why. These proposed studies open new therapeutic avenues to sensitise cancer stem cells to therapy enabling long-term cure.